Compare Organon & Co. (OGN) vs Eli Lilly and Company (LLY) vs Johnson & Johnson (JNJ) Stock

Organon & Co. (OGN) offers the better valuation at 10.1x trailing P/E (2.1x forward), making it the more compelling value choice. Analysts rate Organon & Co. (OGN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Organon & Co. (OGN) is the cheapest at 10.1x versus Eli Lilly and Company at 89.9x. On forward P/E, Organon & Co. is actually cheaper at 2.1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 5.02x versus Johnson & Johnson's 38.22x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +421.2%, compared to -65.2% for Organon & Co. (OGN). A $10,000 investment in LLY five years ago would be worth approximately $52K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1412% versus OGN's -65.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.06β versus Organon & Co.'s 0.92β — meaning OGN is approximately 1557% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 2% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

Eli Lilly and Company (LLY) is the more profitable company, earning 23.5% net margin versus 3.0% for Organon & Co. — meaning it keeps 23.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 38.9% versus 20.7% for OGN. At the gross margin level — before operating expenses — LLY leads at 81.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 5.02x versus Johnson & Johnson's 38.22x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Organon & Co. (OGN) trades at 2.1x forward P/E versus 30.9x for Eli Lilly and Company — 28.8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LLY: 15.4% to $1214.28.

In this comparison, JNJ (2.0% yield), LLY (0.5% yield) pay a dividend. OGN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.06), 2.0% yield, +175.7% 10Y return). Both have compounded well over 10 years (JNJ: +175.7%, OGN: -65.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: OGN is a small-cap deep-value stock; LLY is a large-cap quality compounder stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while OGN, LLY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.